Who is eligible for the TMCi Accelerator for cancer therapeutics? Is company formation required to apply?

To apply to the TMCi Accelerator for cancer therapeutics, researchers and companies should be Texas-based with a cancer therapeutics project. The Accelerator’s priority is to select the highest quality concepts, with the greatest potential. Participants will be required to complete a business grant by the end of the program (SBIR/STTR or CPRIT) and therefore, will need to incorporate during the program.

How do I apply to the Accelerator and what are the important program dates?

Applications open in August and can be completed on the [Accelerator for Cancer Therapeutics webpage](https://www.tmc.edu). Applications close early October. Researchers and companies will be notified of acceptance in November and the Accelerator will commence in January.

How are companies selected for participation in the Accelerator for cancer therapeutics?

Applications are reviewed on a rolling basis, during the open application period, based on the scientific merit, novelty, cancer relevance, and commercial potential of projects. Top ranking applications will be interviewed by the Accelerator team.

What is the cost of the Accelerator? Are program participants provided funding?

The Accelerator is funded by CPRIT through 2024 and offered at no cost to researchers and companies. The Accelerator does not provide funding to participants, does not take equity from participants, and does not generate revenue.

What computational resources are provided, to who, and at what cost?

Computational resources and expert support are offered to competitively selected hit discovery and lead optimization stage projects at no cost to all cancer therapeutics researchers and companies. You are not required to participate in the accelerator to access these resources.

How will my intellectual property be protected?

Academic institutions, investigators, and companies retain the rights to their own intellectual property under discussion or development with the accelerator team. The Program Participation Agreement and the Computational Resources Agreement clearly define these terms.

How does the Accelerator measure program success?

Our goals are to (1) increase Texas-based cancer therapeutic startup companies, (2) support cancer therapeutics companies to secure non-dilutive SBIR/STTR and CPRIT grant funds for continued development, and (3) accelerate the path to IND and clinical trials.

Can I receive support for my cancer therapeutic project if I am not selected for the Accelerator?

Investigators and founders interested in developing cancer therapeutics are encouraged to contact the Accelerator team for office hours [here](https://www.tmc.edu) to receive project specific feedback, individualized coaching, and access to the computational chemistry resources. The Accelerator supports Texas-based companies in the cancer therapeutics at all stages of development.

**act@tmc.edu  www.tmc.edu**

The TMCi Accelerator for cancer therapeutics is funded by the Cancer Prevention and Research Institute of Texas (CPRIT) and launched in collaboration with the Gulf Coast Consortia (GCC) and the University of Texas Medical Branch (UTMB) to support Texas-based biotech entrepreneurs and researchers contemplating translations alongside institutional technology transfer teams.